Biopharma Durect says FDA committee ended meeting with split vote on post-surgical pain treatment [MarketWatch]
DURECT Corporation (DRRX)
Last durect corporation earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
durect.com/investors
Company Research
Source: MarketWatch
Biopharma Durect says FDA committee ended meeting with split vote on post-surgical pain treatment Biopharmaceutical company Durect Corp. DRRX, +3.25% said Friday a U.S. Food and Drug Administration committee ended a meeting to review its Posimir treatment for post-surgical pain with a split vote, as six members voted to recommend the treatment and six voted against. The stock remained halted in premarket trade Friday, continuing a halt first made in premarket trade Thursday, ahead of the meeting. "We are encouraged by the support from a number of the Committee members," Chief Executive James Brown said in a statement. "We continue to believe the data meets all of the regulatory requirements and that the weight of the evidence supports approval. We look forward to working with the agency as it completes its review of the POSIMIR application." The FDA is not obliged to take the recommendation of the committee, called the Anesthetic and Analgesic Drug Products Advisory Committee, alth
Show less
Read more
Impact Snapshot
Event Time:
DRRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRRX alerts
High impacting DURECT Corporation news events
Weekly update
A roundup of the hottest topics
DRRX
News
- DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated HepatitisPR Newswire
- DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- DURECT Co. (NASDAQ: DRRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $5.00 price target on the stock.MarketBeat
- DURECT Co. (NASDAQ: DRRX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- DURECT Co. (NASDAQ: DRRX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
DRRX
Earnings
- 3/27/24 - Beat
DRRX
Sec Filings
- 4/30/24 - Form 8-K
- 3/28/24 - Form 424B5
- 3/28/24 - Form 10-K
- DRRX's page on the SEC website